Background-Past studies of asthma in overweight/obese children have been inconsistent. The reason overweight/obese children commonly report worse asthma control remains unclear. Objective: To determine qualitative differences in symptoms between lean and overweight/obese children with early-onset, atopic asthma.
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The relationship between overweight/obesity and asthma phenotype in children remains inadequately defined. Several large epidemiologic studies have demonstrated that obesity increases the risk of physician-diagnosed asthma 1, 2 and is associated with greater asthmarelated health utilization 3, 4 and asthma that is more problematic and difficult to control. 3, [5] [6] [7] The underlying mechanisms for these associations have proven elusive, and to date little evidence supports obesity worsening asthma through the classic mechanisms of enhanced allergic airway inflammation 8 or airway reactivity. 8, 9 In addition, extensive phenotyping has not confirmed the finding that obesity worsens asthma in all cohorts. [10] [11] [12] [13] This apparent discrepancy regarding the impact of obesity suggests that more in-depth and novel assessments of lean and obese asthmatic children may be required. Specifically, few studies have addressed how obese patients perceive and report asthma symptoms. A greater qualitative understanding of asthma-how it is perceived and reported-may provide an explanation for current discrepancies in the literature on obesity and asthma.
There are several biologically plausible explanations proposed for the link between obesity and greater asthma severity. These include obesity-related comorbidities (eg, depression or gastroesophageal reflux disease [GERD] ), restrictive lung physiology, altered airway perception, and exertional dyspnea erroneously attributed to asthma. In addition, asthmatic patients may be at risk for excess weight gain due to concerns about exercise-induced symptoms. 14, 15 Defining asthma severity in a precise manner can be difficult because it relies on patient-reported subjective symptoms and on self-administered short-acting β-agonist (SABA) use. Symptoms common to asthma can also stem from nonasthma causes and can complicate the assessment of severity. 13 Families often report being confused about self-management and when to administer SABA medications, 16, 17 further challenging the assessment of severity based on SABA use. Therefore, an important public health question for policymakers and clinicians alike is whether obese asthmatic patients are more likely to attribute nonspecific symptoms (eg, breathlessness or digestive symptoms) mistakenly to asthma instead of factors common to obesity, such as increased workload and oxygen demands, GERD, depression/anxiety, and respiratory muscle fatigue. If this attribution error is common, it would explain past findings of excess symptoms and health care utilization among the obese and would suggest that obese asthmatic children are at risk for excessive SABA use, unwarranted controller therapy escalation, and steroid-related side effects.
However, obese children with asthma may sense asthma differently. Heterogeneity in the perception and reporting of asthma exists within the population, 18, 19 as is noted by the example that "poor perceivers" are at an increased risk for near-fatal asthma events. We previously showed that obese children with mild asthma have greater perception of daytoday variation in lung function. 20 This would suggest that obese asthmatic children may have altered sensory perception of airflow limitation and would explain the greater symptoms reported in obese children. Interestingly, Sah et al 13 reported that among children with more severe asthma, obesity was associated with an enhanced perception of nonspecific symptoms. Several governing institutes that support asthma research have called for additional studies comparing qualitative symptoms with existing composite scores to better understand asthma control and standardize its measurement. 21 Objective composite measures of asthma control, quality of life, and symptoms developed by Juniper, 22 Juniper et al, 23, 24 and others [25] [26] [27] include both qualitative and quantitative components. These measures have symptom domains that vary in their specificity to asthma. If obesity worsens the underlying mechanisms of asthma, then qualitative analysis of symptom patterns between lean and obese asthmatic subjects would be expected to be similar. Instead, if obesity increases nonspecific respiratory symptoms and health care utilization via altered sensory-perceptual or emotional-affective factors, 28 then qualitative symptom patterns would be expected to vary substantially between lean and obese asthmatic children. For example, though obese children report greater worsening of composite symptom scores with changes in peak flows, 20 it is not clear specifically what symptoms drive the worsening in asthma control in obese children. If these factors are not better understood, improvements in self-management and health care utilization among the growing number of obese asthmatic subjects may remain difficult. Using directed interviews and validated asthma symptom questionnaires, we sought to define how overweight/obese status affected the pattern and severity of asthma symptoms in children.
METHODS

Participant selection
Children aged between 10 and 17 years with asthma, receiving daily controller therapy, and fitting the age-and sex-adjusted body mass index (BMI) parameters for lean (20-65th percentile) and overweight/obese (BMI ≥ 85th percentile) were enrolled through the Nemours multispecialty pediatric asthma clinic in Jacksonville, Florida. We used common BMI-percentile conventions for overweight/obesity 29,30 and selected from a narrower BMIpercentile range among normal-weight individuals to avoid misclassification. Asthma was defined by accepted convention: physician-diagnosis of asthma and either a 12% or more improvement in FEV 1 after bronchodilation or a PC 20 FEV 1 value of 16 mg/mL or less. 31, 32 Participants were excluded if they had any smoking history, been on controller daily oral steroids, had a change in controller therapy in the previous 8 weeks, had any interval illness in the past 4 weeks, or had another significant chronic disease.
Clinical data
Two to 3 clinic visits within 3 weeks were conducted, with no 2 visits occurring on successive days. At visit 1, participants signed an institutional review board-approved parental permission form and minor assent. Participants completed staff-directed, structured interviews and questionnaires providing asthma and medical history, family and environmental history, quality-of-life information, and a comprehensive interview of asthma symptoms, controller treatment, and past health care utilization. Each participant's controller step prescribed by his or her asthma physician was determined. 33 Participants underwent a physical examination, anthropometric measurements, and spirometry (before and after the administration of a bronchodilator). Highest parental education level, median household incomes, and poverty index (percentage below the poverty level) were determined for each patient's household. Participants completed a methacholine challenge test and exhaled nitric oxide (fraction of exhaled nitric oxide [Feno] ) at visits 2 and 3, respectively, adhering to recommended guidelines. 34, 35 Symptom and quality-of-life analyses Participants and parents answered structured interview questions regarding symptom patterns, common asthma triggers, and the primary symptom experienced with loss of control. The structured interviews also documented asthma symptom frequency and severity, digestive symptoms, and sleep characteristics. Asthma symptom control was assessed at visit 1 using multiple questionnaires (Asthma Control Questionnaire, 23 Asthma Control Test [ACT], 26,36 and childhood ACT 37 ) to measure the broad array of symptoms that asthmatic children experience and report (see Table E1 in this article's Online Repository at www.jacionline.org). Symptoms were measured using the Asthma Symptom Utility Index (ASUI). 27 Asthma-related quality of life was measured using the Paediatric Asthma Quality of Life Questionnaire (PAQLQ) 24,38 and the Paediatric Asthma Caregiver Asthma Quality of Life Questionnaire. 39 Properties of asthma control scores, symptom scores, and asthma qualityof-life scores can be found in this article's Online Repository at www.jacionline.org.
Digestive symptoms
Digestive symptoms were measured using the Pediatric Gastroesophageal Reflux Disease Symptom Assessment Questionnaire, which is a 10-item tool 40 that has been validated in children in the assessment of GERD and digestive symptoms such as chest/abdominal pain, pain/choking with eating, swallowing dysfunction, regurgitation, and nausea. It assesses symptom severity from the previous 7 days on an 8-point scale, with 0 and 7 indicating the least and greatest severity, respectively.
Lung function testing
Participants completed spirometry (Jaeger MasterScreen, San Diego, Calif) adhering to recommended American Thoracic Society standards. 41, 42 Participants also completed Feno (Sievers 280 NOA analyzer, Boulder, Colo) maneuvers according to recommended standards. 43 Participants completed a methacholine challenge by experienced staff using the 10 Provacholine concentrations dosing scheme with a 5-breath dosimeter protocol. 34
Statistical analysis
Study variables were summarized by BMI group (lean and overweight/ obese). Quantitative variables were summarized using mean, SD, and number of subjects, while categorical variables were summarized by number of subjects and percentages. The χ 2 test (or the Fisher exact test) was used for comparing categorical variables between groups, while the Student t test or the Wilcoxon-Mann-Whitney U test (whichever was appropriate) was used to compare quantitative variables between BMI groups. Analyses of covariances were used to detect the effect of BMI status on various asthma symptom control measures. A priori variables used in the model included age, race, ethnicity, sex, and atopy status, along with influential variables found in simple linear regression. Assumptions were checked before using a model, and appropriate steps were taken in case of any violation of assumptions. All tests were 2-tailed at a level of significance of .05. The statistical packages SAS, version 9.1.2 (SAS Institute Inc, Cary, NC), was used.
RESULTS
Characteristics of lean and overweight/obese participants
A total of 74 children and families were screened for eligibility. Fifty-eight children were enrolled, and 96% conducted all 3 clinic visits. Baseline characteristics of lean and overweight/obese participants completing the study (n = 56) are given in Table I . Anthropometric measures were significantly greater in the overweight/obese group. Overweight/obesity status was not associated with age, sex, race, ethnicity, parental education received, measures of socioeconomic status, exposure to secondhand tobacco smoke, or in utero maternal smoke exposure (data not shown). The overweight/obese group had a lower mean gestational age and higher weight at birth though neither reached statistical significance.
Overweight/obese children with asthma experienced significantly different sleep and digestive symptoms than did lean children (Table I) . Among overweight/obese children, 41% reported GERD symptoms at enrollment. Overweight/obese children had significantly higher total GERD scores (9.6 vs 23.2; P = .003) and displayed higher frequency and severity in all GERD assessment domains. Nighttime snoring was a common complaint in the overweight/obese group, though there was no significant difference in reported obstructive sleep apnea, sleep disturbances, or duration. The prevalence of sinopulmonary infections, allergic diseases, or psychiatric conditions was not different between BMI groups.
Lung function and airway measures
Baseline spirometry and changes after the administration of a bronchodilator were similar between lean and overweight/obese asthmatic children (Table II) . Both BMI groups displayed clinically significant airway hyperresponsiveness measured by methacholine challenge; however, lean children had a significantly lower median PC 20 FEV 1 . The overweight/obese group had a significantly lower mean Feno level than did lean children.
Treatment burden and health care utilization
Median controller treatment step was not significantly different between BMI groups (Fig  1) , and groups had similar prevalences of inhaled corticosteroid-long-acting β-agonist combination therapy and leukotriene receptor antagonist medication use (data not shown). In addition, health care utilization defined by reported unscheduled clinic visits (including emergency room visits), hospitalizations, and intensive care utilization was similar between groups (data not shown). Despite these similarities, overweight/obese children reported more than 3 times rescue bronchodilator use per week (3.7 vs 1.1, P =.0002) (Fig 1) .
Primary patient-identified triggers, symptoms, and activity impairment
Roughly two-thirds of all children reported that allergies, viruses, and exercise all were common triggers of asthma symptoms. Just over 50% of all children reported that tobacco smoke was a common trigger. Overweight/obesity status did not affect the prevalence of common triggers (Fisher exact test; P >.382 for all). Overweight/obese children also reported similar activities that were most impaired by uncontrolled symptoms (data not shown). However, lean and overweight/obese children reported significantly different patterns of primary symptom seen with loss of asthma control (Table III) . Overweight/obese children were more likely to identify shortness of breath (odds ratio = 11.8; 95% CI, 1.41-98.7) and less likely to identify cough (odds ratio = 0.26; 95% CI, 0.08-0.82) than were lean children as the primary symptoms with loss of control.
Symptom characterization in lean and overweight/ obese children
Overweight/obese children reported significantly worse asthma symptoms using the composite 6-item Asthma Control Questionnaire without the FEV 1 component (ACQ6), ASUI, ACT, and childhood ACT (Table IV) . In all 4 questionnaires, overweight/obesity significantly negatively affected both the shortness-of-breath and short-acting rescue medication frequency subscales. None of the subscales relating to cough or nocturnal symptoms was affected by overweight/obesity. Overweight/obese children experienced lower asthma-related quality of life that was clinically and statistically significant than did lean children (Table V) . The subdomains (Symptom, Activity, and Emotional) within the PAQLQ each showed a lower mean value (indicating reduced quality of life) among overweight/obese children. When similar asthma-related quality-of-life symptom questions were asked of caregivers using the Paediatric Asthma Caregiver Quality of Life Questionnaire, no overweight/obesity effect was present (Table V) . The only mean difference reported among caregivers of overweight/obese children was a greater worry about medication side effects (Wilcoxon test; P = .026).
Impact of covariables
The effect of obesity was analyzed after adjusting for covariables associated with obesity. In each analysis that accounted for the GERD score in the model, we found that the effect of obesity on asthma control (ACQ6) was eliminated (Table VI) . These results were further validated when ASUI, ACT, and childhood ACT were used as the dependent variable in the model.
DISCUSSION
This study showed that overweight/obese children with early-onset, persistent asthma reported symptoms that were clinically and statistically worse than those reported by similar lean participants. We found that the worse asthma among overweight/obese children consistently involved the report of shortness of breath and greater SABA use and was not driven by greater cough or nighttime awakenings. Lean and overweight/obese children reported substantively different primary symptoms with the onset of loss of asthma control, with overweight/obese children more often reporting shortness of breath and less often reporting cough. Overweight/obese children had clinically and statistically greater gastrointestinal symptoms reported by GERD score. Although BMI affected asthma symptoms when reported by children, similar BMI differences in asthma control were not seen when reported by caregivers. When GERD symptoms were assessed in multivariable modeling, we found that asthma symptom differences between lean and overweight/obese children were abolished. These data suggest that overweight/obese children with asthma on average experience and report asthma differently than do lean children and that the greater obesity-related poor asthma control is driven to a large extent by shortness of breath and self-medication with SABAs. These excess symptoms may not stem technically from asthma but rather from obesity-related sequelae such as GERD, chest restriction, or excess demand on the respiratory system. Instead of obesity-related GERD and chest restriction mediating worse asthma, these processes may cause dyspnea, which is confused for asthma and leads to worse patient-reported asthma control scores.
Both BMI groups were similar by most important demographic and individual characteristics. Exceptions included significantly greater body circumferences, waist-toheight ratio, and GERD prevalence. Weight status did not affect baseline spirometry or bronchodilator changes, while overweight/obese children displayed reduced eosinophilic airway inflammation measured by Feno and airway responsiveness measured by methacholine PC 20 FEV 1 . Most of the overweight/obese patients reported that environmental allergies triggered their asthma. Despite a similar prevalence of allergy triggering, lean patients had significantly higher (>2×) Feno levels, which likely reflects more allergic airway inflammation. Both BMI groups had low PC 20 FEV 1 values, suggesting significant hyperresponsiveness; however, the median methacholine concentration in overweight/obese children was more than 4 times the concentration in lean children, suggesting a substantial difference in airway responsiveness. Excess T H 1 mechanisms that have been associated with obesity 44, 45 may serve to ameliorate allergic airway inflammation, resulting in both lower Feno and reduced airway hyperresponsiveness.
We found that the dose of daily inhaled steroid, prevalence of inhaled corticosteroid-longacting β-agonist combination therapy, prevalence of leukotriene modifiers, and final controller step were similar in both groups. Despite similar controller therapy and significantly reduced airway reactivity, the overweight/obese patients reported selfadministered SABA at more than 3 times the rate reported by lean children. Even with greater SABA use, overweight/obese patients did not report greater recent hospitalizations or urgent care. When overweight/obese patients lost asthma control, they were significantly more likely to report shortness of breath and less likely to report cough. Sah et al 13 recently reported greater shortness of breath and nocturnal cough among obese children with severe asthma. The primary symptom tool used was the ACQ6, 20,46,47 which showed a clinically meaningful difference between lean and overweight/ obese children (0.68 vs 1.26; P = .021).
The minimally important difference (MID) for the ACQ6 is near 0.5. 48 Differences between the BMI groups also exceeded the MID for the ASUI (MID = 0.15) 31 and the ACT (MID = 3). 37 Across multiple assessments, overweight/obese children had worse asthma control due primarily to dyspnea and need for rescue medication use, while none of the 4 validated questionnaires found overweight/obese children to have greater nocturnal symptoms, in contrast to Sah et al's 13 recent findings. This is important because asthma-related sleep disturbance is of major emphasis in current management guidelines. 49, 50 Cough, which is a well-understood and recognizable symptom for families (as opposed to the concept of "wheeze"), was not reported differently between lean and overweight/obese children. We noted that overweight/obese status was significantly associated with worse asthma-related quality of life when symptoms were reported directly by the child (PAQLQ), while a BMIrelated difference was not seen when symptoms for the same children were reported by the caregiver (Paediatric Asthma Caregiver Quality of Life Questionnaire). We speculate that because overweight/obese effect is driven primarily by dyspnea and not cough, caregivers may not fully appreciate their child's symptoms. Alternatively, caregivers of obese children may not attribute the excess impairment-primarily dyspnea and SABA use-to asthma.
Multivariable models that included a priori demographic variables and influential independent variables suggest that the GERD score is an independent predictor of asthma control in overweight/obese children. The GERD score was a significant independent factor in ASUI, ACQ6, and PAQLQ (P < .001 for each). When demographic and significant covariables were included in the multivariable model, the effects of overweight/ obesity on symptom control and quality of life were eliminated. These findings are consistent with the obesity effect on asthma being mediated through GERD. 51, 52 However, this explanation seems unlikely because GERD-induced asthma would also be expected to induce greater cough and airway reactivity, 53 which was not seen. GERD could induce esophageal symptoms interpreted by the patient as shortness of breath and mistakenly attributed to asthma. It has been proposed that dyspnea may stem from repeated respiratory afferent signals to the cerebral cortex, eliciting a repeated sensation/awareness of conscious breathing. 54 Respiratory sensations are the result of neural gating into the cerebral cortex of respiratory afferent input, eliciting a cognitive awareness of breathing and an affective response. 55 If true, repeated esophageal stimulation (from obesity-related GERD) and subsequent neurally mediated tachykinin signaling in the airway 56 could provide this repeated afferent signal and explain the excess dyspnea in our obese patients with GERD. However, because of the cross-sectional nature of this study, we cannot determine whether GERD mediates the association between obesity and dyspnea. Future studies that measure esophageal stimulation and subsequent airway and sensory responses may prove insightful.
The recent American Thoracic Society statement on dyspnea describes its complex nature, which includes various qualitatively distinct sensations and affective distress. 28 These distinct sensations likely arise from distinct sensory mechanisms. Dyspnea upon exertion is typically the most prominent symptom reported with obesity 57, 58 and restrictive lung diseases. 59 Data mainly from adults show that obesity negatively affects respiratory system resistance 60, 61 and compliance, 62 expiratory flows 63 and reserve volume, 64 static inspiratory strength, 65 A-a gradient, 66 and oxygen cost of breathing. 67, 68 Obese adults have greater muscle metabolic requirements, 69 greater ventilatory chemoreflex responsiveness, 70 and greater neural respiratory motor drive, 71 which is sure to be relevant in our present approach to assessing asthma severity among obese asthmatic subjects. Dyspnea (which is common in active asthma) can also result from deconditioning and simple obesity. Therefore, a sufferer of both obesity and asthma may not always know the source of breathlessness and may mistake exertional breathlessness for loss of asthma control. We speculate that much of the problematic nature of asthma among obese children with early-onset, allergic asthma stems in part from heightened airflow perception (ie, sensory-perceptual experience) and altered affective distress with GERD, leading to a sensation of breathlessness. 28 A recent trial in children with pH probe-confirmed GERD and poor asthma control did not find improved asthma outcomes with pharmacologic acid-suppression. 31 Lack of asthma improvement with acid suppression suggests that if GERD is important in creating breathlessness, the refluxate pH is not an important factor. Interestingly, SABA use, which was markedly greater in our overweight/obese group, has been shown to reduce lower esophageal sphincter tone, 72 which is consistent with the pattern of symptoms seen in our overweight/obese cohort and would be consistent with a cycle of GERD, chest symptoms, and more SABA use.
Because dyspnea from asthma is a major driver of anxiety, reduced quality of life, health care utilization, and medication use, a greater understanding of the distinct sensory mechanisms of dyspnea is needed. Until systematic weight loss interventions become more feasible, respiratory physicians may serve their patients better by considering and discussing alternative causes of dyspnea in self-management plans and discussing when SABA use is warranted for obese patients with asthma.
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TABLE V
Differences between child-and caregiver-reported asthma-related quality of life 
